Trial Profile
A randomized, double-blind, placebo-controlled, parallel-group study using the environmental exposure unit (EEU) to assess the onset of action of ciclesonide, applied as a nasal spray (200 mg, once daily), in the treatment of seasonal allergic rhinitis (SAR) in patients 18 years and older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2016
Price :
$35
*
At a glance
- Drugs Ciclesonide (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors ALTANA Pharma
- 06 May 2008 New trial record.